Andrews MC, Chen WS, Spencer C, et al. Molecular, immune and microbial predictors of response and toxicity to combination immune-checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017, abstract SMR02-3.
(Neo)adjuvant erlotinib plus cisplatine verbetert uitkomsten bij stadium III NSCLC
okt 2018 | Longoncologie